Clinical trial · Interventional
ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening
Increasing Access to Colorectal Cancer Screening Among Immigrants
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this randomized trial is to test the effect of a reminder telephone call in the official native language in the country where the invitee is born, in addition to the reminder letter in Norwegian on participation in the National Colorectal Cancer Screening Program in Pakistani and Somalian immigrants, compared to the reminder letter in Norwegian only. The main question it aims to answer is: •Does a reminder telephone call in the language of origin increase participation in colorectal cancer screening in Pakistani and Somalian immigrants in Norway? Participants in this trial are individuals with Pakistan or Somalia as their country of birth invited to the National Colorectal Cancer Screening Program, who have not participated by mailing a faecal sample to the screening laboratory. In the intervention group, the participants will be called in the official language in their country of origin, to inform about colorectal cancer screening, in addition to the reminder letter in Norwegian language sent to all non-participants. Participants in the comparison group will only be sent the reminder letter in Norwegian language. The researchers will compare differences in the participation rate in the National Colorectal Cancer Screening Program between the intervention and comparison groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Colorectal | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Reminder telephone call | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Reminder telephone call
- description
- A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
- interventionNames
- Behavioral: Reminder telephone call
- type
- NO_INTERVENTION
- label
- Comparison
- description
- The reminder letter in Norwegian (usual care) only
Primary outcomes (1)
- measure
- First round screening participation
- timeFrame
- within 12 weeks (84 days) from mailing of the screening reminder letter
- description
- Participation rate in the first colorectal cancer screening round. For each randomized individual, it is measured whether or not the faecal sample is sent to the screening laboratory by the participant in the first round of screening (yes/no).
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Pakistan or Somalia registered as country of birth * Invited to the first round of faecal screening test in the National Colorectal Cancer Screening Program in Norway * Reminder letter sent after no received faecal sample in the screening laboratory within six weeks from mailing of the faecal screening sample kit from the screening organizers Exclusion Criteria: * Individuals whose mailed reminder letter is returned to sender * Individuals whose faecal screening sample is registered in the screening laboratory 1) on the same day or the day after the reminder letter is sent out (applies to those who receive a digital reminder), or 2) on the same day or up to three days after the reminder letter is sent out (applies to those who receive a mailed reminder letter)
References
Publications (1)
- DERIVEDIqbal N, Bhargava S, Hofvind S, Farah KS, Holme O, Botteri E, Berstad P. Effect of reminder phone calls in the language of origin on colorectal cancer screening participation among immigrants in Norway: a randomised controlled trial. Lancet Reg Health Eur. 2026 Mar 13;63:101648. doi: 10.1016/j.lanepe.2026.101648. eCollection 2026 Apr. PMID 41868191